Literature DB >> 18662497

The temporal correlation of dynamic contrast-enhanced magnetic resonance imaging with tumor angiogenesis in a murine glioblastoma model.

Anand Veeravagu1, Lewis C Hou, Andrew R Hsu, Weibo Cai, Joan M Greve, Xiaoyuan Chen, Victor Tse.   

Abstract

OBJECTIVE: Glioblastoma multiforme (GBM) is a WHO grade IV malignant brain tumor with poor prognosis, despite advances in surgical and adjuvant therapy. GBM is characterized by areas of central necrosis and high levels of angiogenesis, during which increased vascular permeability allows for the extravasation of endothelial progenitor cells to support blood vessel and tumor growth. The purpose of this study was to characterize changes in tumor vascular permeability, vascular density and vessel morphology in vivo during angiogenesis.
METHODS: An orthotropic murine (GL26) glioblastoma model was used in this study. in vivo serial dynamic contrast-enhanced magnetic resonance imaging (DCE-MRI) in combination with histologic and molecular genetic analyses was performed to correlate in vivo imaging of vascular development.
RESULTS: DCE-MRI revealed a significant change in tumor vessel permeability dependent upon tumor progression and size. Time to max signal intensity displayed a stepwise increase between days 21 and 24 (p<0.05), a critical period before exponential tumor growth during which a significant increase in tumor vascular density and vessel caliber is observed on histology. Furthermore, quantitative real-time PCR revealed a corollary increase in angiogenic signaling molecules before the observed changes on DCE-MRI. DISCUSSION: In vivo changes of orthotopic glioma blood vessel permeability as shown by DCE-MRI correlates with histologic quantification of vascular density and vessel caliber as well as with the molecular expression of angiogenic factors. DCE-MRI is a useful tool for non-invasive in vivo monitoring of angiogenesis in pre-clinical tumor models.

Entities:  

Mesh:

Substances:

Year:  2008        PMID: 18662497     DOI: 10.1179/174313208X322761

Source DB:  PubMed          Journal:  Neurol Res        ISSN: 0161-6412            Impact factor:   2.448


  9 in total

Review 1.  Role of endolysosomes and inter-organellar signaling in brain disease.

Authors:  Zahra Afghah; Xuesong Chen; Jonathan D Geiger
Journal:  Neurobiol Dis       Date:  2019-11-09       Impact factor: 5.996

2.  Dynamic magnetic resonance imaging assessment of vascular targeting agent effects in rat intracerebral tumor models.

Authors:  Leslie L Muldoon; Seymur Gahramanov; Xin Li; Deborah J Marshall; Dale F Kraemer; Edward A Neuwelt
Journal:  Neuro Oncol       Date:  2010-12-01       Impact factor: 12.300

Review 3.  MR imaging features of high-grade gliomas in murine models: how they compare with human disease, reflect tumor biology, and play a role in preclinical trials.

Authors:  A R Borges; P Lopez-Larrubia; J B Marques; S G Cerdan
Journal:  AJNR Am J Neuroradiol       Date:  2011-12-22       Impact factor: 3.825

4.  Firefly luciferase-based dynamic bioluminescence imaging: a noninvasive technique to assess tumor angiogenesis.

Authors:  Amy Sun; Lewis Hou; Tiffany Prugpichailers; Jason Dunkel; Maziyar A Kalani; Xiaoyuan Chen; M Yashar S Kalani; Victor Tse
Journal:  Neurosurgery       Date:  2010-04       Impact factor: 4.654

Review 5.  Radiation-agent combinations for glioblastoma: challenges in drug development and future considerations.

Authors:  Charles A Kunos; Evanthia Galanis; Jeffrey Buchsbaum; Qian Shi; Lewis C Strauss; C Norman Coleman; Mansoor M Ahmed
Journal:  J Neurooncol       Date:  2017-05-30       Impact factor: 4.130

6.  A dedicated automated injection system for dynamic contrast-enhanced MRI experiments in mice.

Authors:  Jan Sedlacik; Adrianne Myers; Ralf B Loeffler; Regan F Williams; Andrew M Davidoff; Claudia M Hillenbrand
Journal:  J Magn Reson Imaging       Date:  2012-09-21       Impact factor: 4.813

7.  Preclinical efficacy of the anti-hepatocyte growth factor antibody ficlatuzumab in a mouse brain orthotopic glioma model evaluated by bioluminescence, PET, and MRI.

Authors:  Erik S Mittra; Hua Fan-Minogue; Frank I Lin; Jason Karamchandani; Venkataraman Sriram; May Han; Sanjiv S Gambhir
Journal:  Clin Cancer Res       Date:  2013-08-27       Impact factor: 12.531

8.  Early detection of antiangiogenic treatment responses in a mouse xenograft tumor model using quantitative perfusion MRI.

Authors:  Reshmi Rajendran; Wei Huang; Annie Mei Yee Tang; Jie Ming Liang; Stephanie Choo; Torsten Reese; Hannes Hentze; Susan van Boxtel; Adam Cliffe; Keith Rogers; Brian Henry; Kai Hsiang Chuang
Journal:  Cancer Med       Date:  2014-01-06       Impact factor: 4.452

9.  Understanding the Uptake of Nanomedicines at Different Stages of Brain Cancer Using a Modular Nanocarrier Platform and Precision Bispecific Antibodies.

Authors:  Zachary H Houston; Jens Bunt; Kok-Siong Chen; Simon Puttick; Christopher B Howard; Nicholas L Fletcher; Adrian V Fuchs; Jiwei Cui; Yi Ju; Gary Cowin; Xin Song; Andrew W Boyd; Stephen M Mahler; Linda J Richards; Frank Caruso; Kristofer J Thurecht
Journal:  ACS Cent Sci       Date:  2020-04-28       Impact factor: 14.553

  9 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.